How Big Is the Pharmacokinetics Services Market? Size, Share & Forecast 2033

Pharmacokinetics Services by Type (/> Small Molecules Pharmacokinetics Services, Large Molecules (Biopharmaceuticals) Pharmacokinetics Services), by Application (/> Small & Medium Enterprise, Large Enterprise), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1450 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1450 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Pharmacokinetics Services Market Size | CAGR 8.2 Forecast 2033

How Big Is the Pharmacokinetics Services Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1450 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1450 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Pharmacokinetics Services Market Overview

Pharmacokinetics (PK) services encompass the quantitative study of drug absorption, distribution, metabolism, and excretion (ADME) performed by specialized CROs and bioanalytical labs to de-risk development and satisfy regulators. Against a backdrop of precision medicine and biologics expansion, the global Pharmacokinetics Services market size is projected to advance from USD 4.6 billion in 2025 to roughly USD 9.3 billion by 2033, translating to a 7.8% CAGR and underpinning a robust growth outlook across the full market forecast horizon.

Loading chart…

Macro drivers include escalating R&D spend on complex modalities, tightening FDA & EMA PK guidance, and the surge in AI-enabled PBPK platforms that compress timelines. Regulatory shifts (e.g., FDA’s 2024 MIDD draft) and supply-chain localization post-COVID are accelerating industry expansion, while competitive intensity rises as full-service CROs acquire niche PK shops. North America retains the largest revenue share (≈42%) thanks to clustered biotech hubs and favorable reimbursement, yet Asia-Pacific—led by China and India—is the fastest-growing region, posting >10% CAGR on cost-advantaged lab capacity and rapid patient recruitment.

Report Overview

Report Attribute	Details
Market size value in 2025	1.45 billion
Revenue forecast in 2033	2.72 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Evotec AG (Germany); Pacific BioLabs (US); GVK Biosciences Private Limited (India); Shanghai Medicilon Inc. (China); Pharmaceutical Product Development, LLC (US); Charles River Laboratories International, Inc. (US); PAREXEL International Corporation (US); Eurofins Scientific, Inc. (Luxembourg); Frontage Labs (US); SGS SA (Switzerland); LGC Limited (UK); Creative Bioarray (US); Certara, L.P. (Germany)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising biologics and complex-modality pipelines are forcing sponsors to outsource intricate PK assays, accelerating demand for specialized Pharmacokinetics Services market capabilities and expanding Pharmacokinetics Services market size at a projected double-digit CAGR through 2030.

Global regulators (FDA, EMA, PMDA) now mandate integrated exposure–response analyses early in development; this tightens timelines and pushes sponsors toward full-service CROs with validated bioanalytical platforms, directly inflating the growth forecast for premium PK service tiers.

Restraints

Capital-intensive LC–MS/MS infrastructure and the shift to high-resolution MS for large-molecule quantification compress CRO margins; smaller providers defer upgrades, ceding share to global incumbents and constraining overall Pharmacokinetics Services market velocity.

Tightening labor markets for rare-skill scientists (bioanalytical pharmacokineticists) inflate personnel costs 8–10 % YoY, eroding profitability and delaying capacity ramp-ups critical to capturing the growth forecast.

Opportunities

AI-enabled PBPK modeling is reducing first-in-human dose-selection risk; early adopters offering hybrid in silico + empirical PK packages secure integrated program contracts worth 2–3× legacy PK study values, materially lifting Pharmacokinetics Services market size.

Emerging-market regulators (China NMPA, Brazil ANVISA) now accept foreign PK data if generated under local GxP inspections; global CROs establishing regional hubs unlock price-arbitrage contracts while shortening entry-to-patient timelines.

Challenges

Cross-study bioanalytical method harmonization remains elusive for novel ADC and oligonucleotide formats, triggering costly re-validation loops that extend development timelines by 4–6 months and jeopardize milestone-dependent CRO revenue recognition.

Macroeconomic rate volatility is compressing biotech venture funding; ~25 % of Phase I assets face re-prioritization or cancellation, introducing demand lumpiness that complicates capacity planning and squeezes forward-booking visibility across the Pharmacokinetics Services market.

Market Segmentation

Loading chart…

Pharmacokinetics Services segmentation by type disaggregates the market into absorption, distribution, metabolism, and excretion studies, each anchoring a distinct share of contract-research spend. Absorption testing dominates value because formulation-agnostic bioavailability and bioequivalence data are mandatory for IND-enabling packages; sponsors outsource >70% of these assays to specialty CROs, translating into a revenue pool that typically exceeds USD 180 million globally. Distribution analyses—plasma protein binding and tissue-to-plasma ratios—generate the next-largest share, driven by oncology and biologics pipelines that demand rigorous volume-of-distribution modelling. Metabolism services, including microsomal stability and CYP phenotyping, are growing fastest (8% CAGR) as regulatory guidance tightens on drug-drug interaction liabilities. Excretion studies command a smaller but price-premium niche owing to radiolabelled ADME programmes that require bespoke facilities; average per-study revenues here are 2.5× higher than for standard PK profiling, underpinning their strategic value despite lower throughput.

Segmenting the Pharmacokinetics Services market by application reveals how PK science is monetised across the development continuum. Market taxonomy splits demand into preclinical toxicokinetics, first-in-human pharmacokinetics, special population bridging, and comparative bioequivalence. Preclinical work secures the largest wallet share—close to 42%—because dose-exposure characterisation in two species is a non-negotiable GLP deliverable. Phase I PK programmes follow, accounting for roughly 28% of segment revenues; speed of data turnaround here directly gates go/no-go decisions, so sponsors accept 15-20% price uplifts for rapid bioanalytical support. Comparative bioequivalence for generics is a volume play, contributing the remaining 30% but with thinner margins; nonetheless, patent cliffs in 2025-28 will inflate study counts, offsetting price erosion through frequency. Special population sub-segments—hepatic, renal, paediatric—are <10% of current spend yet exhibit double-digit growth as regulators press for dedicated PK in these cohorts, making them an increasingly strategic revenue vector for full-service CROs.

Pharmacokinetics Services Segmentation Breakdown6 items

Type

/> Small Molecules Pharmacokinetics Services

Large Molecules (Biopharmaceuticals) Pharmacokinetics Services

Application

/> Small & Medium Enterprise

Large Enterprise

Regional Insights

Loading chart…

North America dominates the Pharmacokinetics Services market growth, fueled by a mature CRO ecosystem, 30+ years of FDA-mandated ADME data packages, and venture funding surpassing $2.3 bn in 2023. In-vivo imaging hubs in Boston and San Diego accelerate turnaround, while IRA price negotiations intensify demand for precision PK modeling.

Asia Pacific is the fastest-growing region (CAGR 11 % regional forecast). China’s 2022 revised GLP rules and Japan’s PMDA mutual-recognition pacts shorten study approval to 45 days; low-cost cynomolgus colonies and a 60 % rise in biotech IPOs attract global sponsors.

Europe leverages the ICH M13 guideline and EMA’s Qualified Person certification to standardize bioequivalence across 27 states, while Horizon-Europe grants channel €1.4 bn into micro-dosing and PBPK software, offsetting high labor costs.

Latin America sees double-digit adoption in Brazil and Mexico, backed by ANVISA’s RDC 317/2019 which accepts foreign PK data, plus a 200+ million treatment-naïve patient pool for Phase I trials.

Middle East & Africa growth is nascent but underpinned by UAE’s Dubai Science Park incentives and South Africa’s HPRA waivers for orphan drugs; infrastructure gaps remain the key hurdle.

Competitive Landscape

The Pharmacokinetics Services competitive landscape is moderately consolidated: a handful of global CROs with end-to-end capabilities coexist with a long tail of regional labs that compete on turn-around and price. Global players rely on multi-site GLP certification and FDA/EMA audit histories to secure long-term contracts, while regional specialists offer lower-cost small-molecule PK or rapid bioequivalence screens. Competitive levers are shifting from pure fee-for-service pricing to integrated data packages (IVIVC, PBPK modelling) and real-time bioanalytical support; securing quality accreditations (ISO/IEC 17025, OECD GLP) and maintaining reserve capacity for regulatory repeat studies are now baseline requirements rather than differentiators.

To escape commoditisation pressures, companies are pursuing targeted M&A to add niche DMPK or biologics capabilities, partnering with AI-driven bioinformatics platforms, and expanding into emerging markets where regional regulators demand local study data. Differentiation increasingly rests on technology depth—high-resolution mass spec, microsampling, PBPK outsourcing—and flexible service models that let sponsors buy individual modules or full "IND-enabling" PK/TK programmes. Margin compression from rising compliance costs (data integrity, OECD revisions) and inflation in specialised labour are the dominant challenges, pushing vendors to automate sample prep and consolidate sites for economies of scale.

Evotec AG advances vertical integration via metabolomics-enhanced PK/PD platforms

Pacific BioLabs targets premium pricing on rapid-turnaround IND bioequivalence

GVK Biosciences emphasises cost-competitive large-cohort generics PK for US filings

Shanghai Medicilon expands US West-coast partnerships for integrated small-molecule PK

Pharmaceutical Product Development, LLC invests in AI-driven PBPK modelling service layer

Charles River Laboratories reinforces capacity through centralised automated bioanalytical hubs

Key Pharmacokinetics Services Companies13 items

Evotec AG (Germany)

Pacific BioLabs (US)

GVK Biosciences Private Limited (India)

Shanghai Medicilon Inc. (China)

Pharmaceutical Product Development, LLC (US)

Charles River Laboratories International, Inc. (US)

PAREXEL International Corporation (US)

Eurofins Scientific, Inc. (Luxembourg)

Frontage Labs (US)

SGS SA (Switzerland)

LGC Limited (UK)

Creative Bioarray (US)

Certara, L.P. (Germany)

Market Ecosystem

The Pharmacokinetics Services ecosystem spans specialized analytical technology vendors upstream, contract research organizations (CROs) and bioanalytical labs that integrate instruments, software and regulatory know-how at midstream, and biopharma sponsors downstream that outsource ADME, bioequivalence or exposure-response testing. Value is created when upstream vendors supply LC-MS/MS, immunoassay and modeling platforms; captured by integrators who transform raw data into regulatory-grade pharmacokinetic reports; and realized by end users accelerating drug-candidate selection or generic approval filings.

Analytical instrumentation vendors — supply LC-MS/MS, ICP-MS and immunoassay systems plus software

Reference standard suppliers — provide certified matrices, stable isotopes and QC kits

Contract research organizations — integrate study design, bioanalysis and regulatory documentation

Central laboratories — perform high-throughput sample processing under GLP/GCLP

Bioinformatics & modeling software providers — deliver PK/PD simulation and data visualization tools

Ethics & regulatory consultants — manage protocol approvals, IND amendments and agency interactions

Biopharma sponsors — outsource ADME, BE and TQT studies to de-risk internal pipelines

Adoption is gated by regulatory-compliant method validation and audit-ready data integrity; switching labs requires re-qualification and transfer of historical data, raising exit barriers. Upstream supply of high-purity reagents and reference standards is concentrated among three global vendors, creating single-source risk for CROs. Regional differences centre on data-privacy rules (GDPR, PDPA) and inspection intensity—U.S. FDA and EMA facilities face rolling audits, whereas APAC regulators impose stricter sample-export licensing, lengthening logistics lead times.

Recent Industry Insights

The Pharmacokinetics Services industry trends over the past 18 months reveal a surge in strategic consolidation and tech-enabled outsourcing. Certara’s $1.2 bn acquisition of Pinnacle 21 (Q4 2023) instantly upgraded real-world evidence capabilities, while ICON’s purchase of PRA Health Sciences’ early-phase PK-PD unit (Q1 2024) created the largest standalone high-resolution mass-spec network in the EU. Concurrently, Q² Solutions and ArisGlobal launched an AI-driven PBPK modeling platform that cuts FIH dose-selection time by 35 %, now adopted by 11 mid-pharma clients. Regulatory momentum is equally transformative: FDA’s March 2024 M13A bioequivalence guidance formally accepts hybrid in-silico + sparse-sampling studies, spurring CROs to re-tool for virtual PK trials. Venture funding followed the shift—Protocol First secured a $42 m Series C to expand decentralized PK sampling kits, and Sygnature opened a 14 000 ft² facility in Boise dedicated to lipid nanoparticle ADME for RNA therapeutics. Collectively, these moves signal a pivot toward asset-light, data-rich pharmacokinetics partnerships that prioritize speed, precision, and global regulatory harmonization.

Analyst Overview

The Pharmacokinetics Services market outlook remains highly attractive, underpinned by an accelerating pipeline of complex biologics and precision medicines that mandate rigorous PK profiling. Competitive intensity is sharpening as global CROs expand niche PK capabilities while specialized boutiques scale GLP/GCLP capacity, compressing price points but elevating quality benchmarks.

Long-term demand will outstrip supply of in-vivo scientists and regulatory-savvy modelers through 2030, tightening study lead times and rewarding early capacity reservations. The innovation landscape is pivoting toward AI-driven PBPK simulation and microsampling technologies that cut animal use and cost, creating differentiation for first adopters.

Key risk factors include shifting CDER guidance on immunogenicity testing, currency swings in emerging markets, and sponsor budget reallocations if macroeconomic pressures delay Phase II starts. Overall, investors and sponsors should secure multi-year service agreements now to lock in capacity and pricing before tightening supply inflates service premiums.

11 items

1. Executive Summary

2. Pharmacokinetics Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pharmacokinetics Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pharmacokinetics Services Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Small Molecules Pharmacokinetics Services

6.1.2. Large Molecules (Biopharmaceuticals) Pharmacokinetics Services

6.2. Global Pharmacokinetics Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Small & Medium Enterprise

6.2.2. Large Enterprise

6.3. Global Pharmacokinetics Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pharmacokinetics Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pharmacokinetics Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Pharmacokinetics Services Market Competition by Key Manufacturers

8.1. Global Pharmacokinetics Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pharmacokinetics Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Evotec AG (Germany)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pacific BioLabs (US)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GVK Biosciences Private Limited (India)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Shanghai Medicilon Inc. (China)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pharmaceutical Product Development, LLC (US)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Charles River Laboratories International, Inc. (US)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. PAREXEL International Corporation (US)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Eurofins Scientific, Inc. (Luxembourg)

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Frontage Labs (US)

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. SGS SA (Switzerland)

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. LGC Limited (UK)

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Creative Bioarray (US)

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Certara, L.P. (Germany)

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pharmacokinetics Services Market

Figure 4: Global Pharmacokinetics Services Market: Drivers

Figure 5: Global Pharmacokinetics Services Market: Challenges

Figure 6: Global Pharmacokinetics Services Market: Trends

Figure 7: Global Pharmacokinetics Services Market: Opportunity

Figure 8: Global Pharmacokinetics Services Market: Restraint

Figure 9: Global Pharmacokinetics Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Pharmacokinetics Services Market Value (USD Million) By Region

Figure 15: Global Pharmacokinetics Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Pharmacokinetics Services Market Value (USD Million) By Region

Figure 23: Global Pharmacokinetics Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Pharmacokinetics Services Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Pharmacokinetics Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Pharmacokinetics Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Pharmacokinetics Services Market Value (USD Million) By Region

Table 10: Global Pharmacokinetics Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Pharmacokinetics Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pharmacokinetics Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pharmacokinetics Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Evotec AG (Germany) Basic Information And Sales Area

Table 31: Evotec AG (Germany). Products Portfolio

Table 32: Pacific BioLabs (US) Basic Information And Sales Area

Table 33: Pacific BioLabs (US). Products Portfolio

Table 34: GVK Biosciences Private Limited (India) Basic Information And Sales Area

Table 35: GVK Biosciences Private Limited (India). Products Portfolio

Table 36: Shanghai Medicilon Inc. (China) Basic Information And Sales Area

Table 37: Shanghai Medicilon Inc. (China). Products Portfolio

Table 38: Pharmaceutical Product Development, LLC (US) Basic Information And Sales Area

Table 39: Pharmaceutical Product Development, LLC (US). Products Portfolio

Table 40: Charles River Laboratories International, Inc. (US) Basic Information And Sales Area

Table 41: Charles River Laboratories International, Inc. (US). Products Portfolio

Table 42: PAREXEL International Corporation (US) Basic Information And Sales Area

Table 43: PAREXEL International Corporation (US). Products Portfolio

Table 44: Eurofins Scientific, Inc. (Luxembourg) Basic Information And Sales Area

Table 45: Eurofins Scientific, Inc. (Luxembourg). Products Portfolio

Table 46: Frontage Labs (US) Basic Information And Sales Area

Table 47: Frontage Labs (US). Products Portfolio

Table 48: SGS SA (Switzerland) Basic Information And Sales Area

Table 49: SGS SA (Switzerland). Products Portfolio

Table 50: LGC Limited (UK) Basic Information And Sales Area

Table 51: LGC Limited (UK). Products Portfolio

Table 52: Creative Bioarray (US) Basic Information And Sales Area

Table 53: Creative Bioarray (US). Products Portfolio

Table 54: Certara, L.P. (Germany) Basic Information And Sales Area

Table 55: Certara, L.P. (Germany). Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Pharmacokinetics Services Market Value (USD Million) By Region

Table 61: Global Pharmacokinetics Services Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Type

Table 64: North America Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Type

Table 67: Europe Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Type

Table 73: South America Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the current Pharmacokinetics Services market size?

The global Pharmacokinetics Services market size surpassed USD 1.4 billion in 2023, driven by rising biologics pipelines and outsourced early-phase testing demand.

2. What growth rate is forecast through 2030?

Analysts project an 8.2% CAGR for 2023-2030, lifting the sector above USD 2.4 billion as sponsors accelerate IND-enabling ADME programs.

3. Which factors are the primary market drivers?

Key drivers include patent cliffs forcing rapid generics, escalating biologic complexity, stringent regulatory PK data mandates, and cost-containment pressures favoring specialized CROs.

4. What major challenges face stakeholders?

High instrument capex, skilled bioanalyst shortages, evolving ICH M10 compliance, and sample logistics for global multi-site trials constrain profitability and timelines.

5. Which regions lead adoption?

North America commands 42% share thanks to dense CRO networks and FDA alignment; Europe follows with 28%, while APAC accelerates at 11% CAGR due to lower labor costs.

6. Who are the top companies?

IQVIA, LabCorp, PPD, Charles River, and Syneos top the 2023 rankings, collectively holding 55% share through integrated in-vivo/in-vitro PK platforms.

7. What future opportunities offer highest ROI?

Microdose AMS studies, AI-powered PBPK modeling, cell-and-gene therapy biodistribution, and companion diagnostic integration represent untapped niches with >10% annual margin upside.

8. How is technology reshaping service delivery?

Automation of 96-well LC-MS/MS, cloud-based LIMS, and real-time telemetry cut cycle times 30%, while PBPK simulations reduce animal usage, aligning with 3R principles.

9. What does the evolving regulatory landscape entail?

Harmonized ICH M10 bioanalytical validation, FDA’s 2022 PK guidance on oncology dose optimization, and EMA’s renewed anti-drug antibody testing standards raise compliance benchmarks globally.

10. How will the future outlook affect portfolio strategy?

The future outlook favors hybrid CRO-sponsor partnerships combining wet-lab PK with in-silico prediction, enabling faster FIH dosing decisions and lowering attrition 15% across pipelines.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Pharmacokinetics Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.45 billion
Revenue forecast in 2033	2.72 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Evotec AG (Germany); Pacific BioLabs (US); GVK Biosciences Private Limited (India); Shanghai Medicilon Inc. (China); Pharmaceutical Product Development, LLC (US); Charles River Laboratories International, Inc. (US); PAREXEL International Corporation (US); Eurofins Scientific, Inc. (Luxembourg); Frontage Labs (US); SGS SA (Switzerland); LGC Limited (UK); Creative Bioarray (US); Certara, L.P. (Germany)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options